[HTML][HTML] Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)
JJ Grob, R Gonzalez, N Basset-Seguin… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2020•ncbi.nlm.nih.gov
PURPOSE Treatment options are limited for patients with recurrent and/or metastatic (R/M)
cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with
distant metastases. Here, we present the first interim analysis of the R/M cSCC cohort from
the 2-cohort—locally advanced and R/M—phase II KEYNOTE-629 study.
cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with
distant metastases. Here, we present the first interim analysis of the R/M cSCC cohort from
the 2-cohort—locally advanced and R/M—phase II KEYNOTE-629 study.
Abstract
PURPOSE
Treatment options are limited for patients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with distant metastases. Here, we present the first interim analysis of the R/M cSCC cohort from the 2-cohort—locally advanced and R/M—phase II KEYNOTE-629 study.
ncbi.nlm.nih.gov